Skip to main content

Advertisement

SpringerLink
Log in

An oocyte donation protocol using the GnRH antagonist ganirelix acetate, does not compromise embryo quality and is associated with high pregnancy rates

  • Original Article
  • Published:
Archives of Gynecology and Obstetrics Aims and scope Submit manuscript

Abstract

Purpose: To evaluate the effect of the GnRH antagonist, ganirelix acetate, on oocyte quality. Methods: Stimulation characteristics, implantation rates and clinical pregnancy rates were compared between 29 oocyte donors 21–31 years of age who underwent 31 cycles of ovarian stimulation with gonadotropins and ganirelix acetate, and 36 infertile couples of similar age range who underwent 51 cycles of ovarian stimulation using the same protocol. Results: A significantly lower number of embryos were transferred in the donor/recipient group as compared to the infertile group (2.32±0.54 vs. 2.82±0.71, P<0.05). In contrast, implantation and clinical pregnancy rates per transfer, were significantly higher in the donor/recipient group (38.1% vs. 10.4%, P<0.01) and (61.3% vs. 23.1%, P<0.05) respectively, as compared to the infertile group. Conclusions: Incorporation of ganirelix acetate for pituitary suppression in stimulation protocols for oocyte donation is associated with high pregnancy rates suggesting that ganirelix acetate does not exert an adverse effect on oocyte or embryo quality.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Porter RN, Smith W, Craft IL, Abdulwahid NA, Jacobs HS (1984) Induction of ovulation for in-vitro fertilisation using buserelin and gonadotropins. Lancet 2(8414):1284–1285

    Google Scholar 

  2. Shaw RW, Ndukwe G, Imoedemhe DA, Bernard AG, Burford G (1985) Twin pregnancy after pituitary desensitisation with LHRH agonist and pure FSH. Lancet 2(8453):506–507

    Google Scholar 

  3. Ben-Rafael Z, Lipitz S, Bider D, Mashiach S (1991) Ovarian hyporesponsiveness in combined gonadotropin-releasing hormone agonist and menotropin therapy is associated with low serum follicle- stimulating hormone levels. Fertil Steril 55(2):272–275

    Google Scholar 

  4. Diedrich K, Diedrich C, Santos E, Zoll C, al-Hasani S, Reissmann T et al (1994) Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation. Hum Reprod 9(5):788–791

    Google Scholar 

  5. Albano C, Smitz J, Camus M, Riethmuller-Winzen H, Van Steirteghem A, Devroey P (1997) Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation. Fertil Steril 67(5):917–922

    Google Scholar 

  6. Olivennes F, Fanchin R, Bouchard P, Taieb J, Selva J, Frydman R (1955) Scheduled administration of a gonadotrophin-releasing hormone antagonist (Cetrorelix) on day 8 of in-vitro fertilization cycles: a pilot study. Hum Reprod 10(6):1382–1386

    Google Scholar 

  7. Albano C, Felberbaum RE, Smitz J, Riethmuller-Winzen H, Engel J, Diedrich K et al (2000) Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group. Hum Reprod 15(3):526–531

    Google Scholar 

  8. Borm G, Mannaerts B (2000) Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group. Hum Reprod 15(7):1490–1498

    Google Scholar 

  9. Olivennes F, Belaisch-Allart J, Emperaire JC, Dechaud H, Alvarez S, Moreau L et al (2000) Prospective, randomized, controlled study of in vitro fertilization- embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin). Fertil Steril 73(2):314–320

    Google Scholar 

  10. Al-Inany H, Aboulghar M (2001) Gonadotrophin-releasing hormone antagonists for assisted conception. Cochrane Database Syst Rev 4

  11. Fluker M, Grifo J, Leader A, Levy M, Meldrum D, Muasher SJ et al (2001) Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertil Steril 75(1):38–45

    Google Scholar 

  12. Filicori M, Cognigni GE, Tabarelli C, Pocognoli P, Taraborrelli S, Spettoli D, et al (2002) Stimulation and growth of antral ovarian follicles by selective LH activity administration in women. J Clin Endocrinol Metab 87(3):1156–1161

    Google Scholar 

  13. Filicori M, Cognigni GE, Taraborrelli S, Spettoli D, Ciampaglia W, Tabarelli De Fatis C, et al (2001) Luteinzing hormone activity in menotropins optimizes folliculogenesis and treatment in controlled ovarian stimulation. J Clin Endocrinol Metab 86(1):337–343

    Google Scholar 

  14. Fraser HM, Lunn SF, Morris KD, Deghenghi R (1997) Initiation of high dose gonadotrophin-releasing hormone antagonist treatment during the late follicular phase in the macaque abolishes luteal function irrespective of effects upon the luteinizing hormone surge. Hum Reprod 12(3):430–435

    Google Scholar 

  15. Kolibianakis E, Bourgain C, Albano C, Osmanagaoglu K, Smitz J, Van Steirteghem A et al (2002) Effect of ovarian stimulation with recombinant follicle-stimulating hormone, gonadotropin releasing hormone antagonists, and human chorionic gonadotropin on endometrial maturation on the day of oocyte pick-up. Fertil Steril 78(5):1025–1029

    Google Scholar 

  16. Tavaniotou A, Albano C, Smitz J, Devroey P (2002) Impact of ovarian stimulation on corpus luteum function and embryonic implantation. J Reprod Immunol 55(1–2):123–130

    Google Scholar 

  17. Noyes RW, Hertig AT, Rock J (1975) Dating the endometrial biopsy. Am J Obstet Gynecol 122(2):262–263

    Google Scholar 

  18. Garcia JE, Acosta AA, Hsiu JG, Jones HW Jr (1984) Advanced endometrial maturation after ovulation induction with human menopausal gonadotropin/human chorionic gonadotropin for in vitro fertilization. Fertil Steril 41(1):31–35

    Google Scholar 

  19. Chetkowski RJ, Kiltz RJ, Salyer WR (1997) In premature luteinization, progesterone induces secretory transformation of the endometrium without impairment of embryo viability. Fertil Steril 68(2):292–297

    Google Scholar 

  20. Anonymous (2002) Guidelines for oocyte donation. Fertil Steril 77(6 Suppl 5):S6–S8

    Google Scholar 

  21. Kol S (2000) Embryo implantation and GnRH antagonists: GnRH antagonists in ART: lower embryo implantation? Hum Reprod 15(9):1881–1882

    Google Scholar 

  22. Das K, Stout LE, Hensleigh HC, Tagatz GE, Phipps WR, Leung BS (1991) Direct positive effect of epidermal growth factor on the cytoplasmic maturation of mouse and human oocytes. Fertil Steril 55(5):1000–1004

    Google Scholar 

  23. Dekel N, Sherizly I (1985) Epidermal growth factor induces maturation of rat follicle-enclosed oocytes. Endocrinology 116(1):406–409

    Google Scholar 

  24. Hernandez ER (2000) Embryo implantation and GnRH antagonists: embryo implantation: the Rubicon for GnRH antagonists. Hum Reprod 15(6):1211–1216

    Google Scholar 

  25. Cross JC, Werb Z, Fisher SJ (1994) Implantation and the placenta: key pieces of the development puzzle. Science 266(5190):1508–1518

    Google Scholar 

  26. Hershkovitz E, Marbach M, Bosin E, Levy J, Roberts CT Jr, LeRoith D et al (1993) Luteinizing hormone-releasing hormone antagonists interfere with autocrine and paracrine growth stimulation of MCF-7 mammary cancer cells by insulin-like growth factors. J Clin Endocrinol Metab 77(4):963–968

    Google Scholar 

  27. Kleinman D, Roberts CT Jr, LeRoith D, Schally AV, Levy J, Sharoni Y (1993) Regulation of endometrial cancer cell growth by insulin-like growth factors and the luteinizing hormone-releasing hormone antagonist SB-75. Regul Pept 48(1–2):91–98

    Google Scholar 

  28. Minaretzis D, Jakubowski M, Mortola JF, Pavlou SN (1995) Gonadotropin-releasing hormone receptor gene expression in human ovary and granulosa-lutein cells. J Clin Endocrinol Metab 80(2):430–434

    Google Scholar 

  29. Del Gadillo JC, Siebzehnrubl E, Dittrich R, Wildt L, Lang N (2002) Comparison of GnRH agonists and antagonists in unselected IVF/ICSI patients treated with different controlled ovarian hyperstimulation protocols: a matched study. Eur J Obstet Gynecol Reprod Biol 102(2):179–183

    Google Scholar 

  30. Olivennes F (2002) GnRH antagonists: do they open new pathways to safer treatment in assisted reproductive techniques? Reprod Biomed Online 5(Suppl 1(3)):20–25

    Google Scholar 

  31. Olivennes F, Cunha-Filho JS, Fanchin R, Bouchard P, Frydman R (2002) The use of GnRH antagonists in ovarian stimulation. Hum Reprod Update 8(3):279–290

    Google Scholar 

  32. Albano C, Smitz J, Tournaye H, Riethmuller-Winzen H, Van Steirteghem A, Devroey P (1999) Luteal phase and clinical outcome after human menopausal gonadotrophin/gonadotrophin releasing hormone antagonist treatment for ovarian stimulation in in-vitro fertilization/intracytoplasmic sperm injection cycles. Hum Reprod 14(6):1426–1430

    Google Scholar 

  33. Lewin A, Benshushan A, Mezker E, Yanai N, Schenker JG, Goshen R (1994) The role of estrogen support during the luteal phase of in vitro fertilization-embryo transplant cycles: a comparative study between progesterone alone and estrogen and progesterone support. Fertil Steril 62(1):121–125

    Google Scholar 

  34. Itskovitz-Eldor J, Kol S, Mannaerts B (2000) Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: short communication. Hum Reprod 15(9):1965–1968

    Google Scholar 

  35. Kol S, Itskovitz-Eldor J (2000) Severe OHSS: yes, there is a strategy to prevent it! Hum Reprod 15(11):2266–2267

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Reproductive Endocrinology & Infertility, The Johns Hopkins Hospital, 600 N. Wolfe Street/Phipps 249, Baltimore, MA, 21287-1247, USA

    N. F. Vlahos, B. J. Bankowski, H. A. Zacur, J. E. Garcia, E. E. Wallach & Y. Zhao

Authors
  1. N. F. Vlahos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. J. Bankowski
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. A. Zacur
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. E. Garcia
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E. E. Wallach
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Y. Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to N. F. Vlahos.

Additional information

Capsule: Incorporation of ganirelix acetate in stimulation protocols for oocyte donation is associated with high pregnancy rates suggesting that there is no adverse effect on oocyte quality

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vlahos, N.F., Bankowski, B.J., Zacur, H.A. et al. An oocyte donation protocol using the GnRH antagonist ganirelix acetate, does not compromise embryo quality and is associated with high pregnancy rates. Arch Gynecol Obstet 272, 1–6 (2005). https://doi.org/10.1007/s00404-005-0726-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00404-005-0726-2

Keywords

Search

Navigation